



CAPA e Newsletter



CHINESE AMERICAN PATHOLOGISTS ASSOCIATION

~全美华人病理学会~

VOLUME 14 ISSUE 4 2025

In this issue:

CAPA president messages P1-4

CAPA election committee messages P5-6

Call for application:2026 CAPA Awards P6-9

CAPA members achievements P9-11

Agenda of CAPA 2026 Business meeting P11-12

CAPA 2025-2026 committee chair messages and Upcoming OLE lectures and P13

Acknowledgments of CAPA sponsors P14

Editors
Qiong Zhang
Yu (Sunny) Yang

Editing Team
Chao Chen
Xiao Zhou
Hong Cheng
Liping Li
Larry Wang
Zaibo Li



Message from the President (2025-2026)

*D*ear Colleagues of CAPA:

Happy Holidays!


It is once again my pleasure to share some good news with our CAPA members. Over the past several months, we have made significant progress toward many of our initiatives and goals, thanks to the outstanding efforts of our Education Committees and Subcommittees, Finance Committee, Membership Committee, Professional Partnership Committee, and all of our dedicated volunteers.



1. Education and Professional Development

1) CAPA Digital Platform in Collaboration with PathPresenter

This platform provides CAPA members with seamless access to high-quality educational resources and virtual learning opportunities. To date, the platform has attracted 119 registered CAPA member users, and we anticipate continued growth. Please check it out at the following link: <http://capa.pathpresenter.net>



2) CAPA-CAP Companion Meeting Acknowledgment

During last newsletter, I incidentally omit acknowledgement to several our CAPA-CAP committee members Dr. Pei Hui, Dr. Fang Fan and Dr. Xiaoxian Li for their efforts to recruit speakers for this companion meeting.

2. Fostering Collaboration and Global Engagement

CAPA has always thrived on collaboration, and we continue to expand our global partnerships to promote knowledge exchange and professional development.



1) The 5th CAPA–ASC Companion Meeting

The 5th CAPA-ASC Companion Meeting, “Recent Advances in Precision Cytopathology,” was successfully held during the 73rd ASC Annual Scientific Meeting (November 5-9, 2025) in St. Louis, Missouri. Organized by Drs. Xiaoying Liu, Fang Fan, Tieying Hou, and Xiaohua Qian, and moderated by Dr. Qun Wang, the session highlighted the evolving role of cytopathology in the era of precision medicine.

The program featured expert-led presentations on precision pancreatic, lung, head and neck, and soft tissue cytopathology, with a strong emphasis on specimen stewardship, ancillary testing, and molecular diagnostics. This well-received session underscored CAPA’s expanding national impact and continued commitment to advancing education in precision cytopathology.





2) AP-IAP companion meeting

The 14th Asia Pacific International Academy of Pathology Congress (AP-IAP 2025) was held successfully in Bangkok, Thailand, from November 5–7, 2025, with more than 800 participants in attendance. The Congress featured 124 international and national speakers who delivered 117 lectures and 35 slide seminars spanning a broad range of diagnostic and academic pathology topics.

The Chinese American Pathologists Association (CAPA) was invited to participate, and a CAPA delegation convened a companion meeting during the Congress. The delegation included Drs. Chen Liu, Haodong Xu, Jimmy Yang, Guoping Cai, Shaoxiang Chen, Zhaohai Yang, Bo Xu, Yun Wu, and Larry Wang. CAPA members delivered nine high-quality presentations that drew large audiences and stimulated active discussion (please see the detailed program in a separate section).

In addition, nine other CAPA members attended the Congress and engaged in scientific and professional exchanges. CAPA's contributions were highly appreciated by the AP-IAP organizers, who expressed strong interest in continued collaboration and future CAPA participation in AP-IAP meetings and International Academy of Pathology (IAP) activities.





3) The 4th CAPA-USCAP companion meeting

Under the leadership of Dr. Deyin Xin, the proposal for the 4th CAPA–USCAP Companion Meeting has been approved by USCAP. The meeting will be held on Sunday, March 22, 2026, from 8:00 AM to 10:00 AM at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

This session will feature four expert presentations on rapidly evolving areas in gynecologic and genitourinary pathology. Confirmed speakers include Dr. Natalia Buza (Yale University), Dr. Wenxin Zheng (UT Southwestern), Dr. Maria Tretiakova (University of Washington), and Dr. Ming Zhou (Mount Sinai).

4) German Society of Pathology (DGP)

As part of our continued educational collaboration with DGP, we will invite DGP delegates to participate in the scientific session during CAPA Annual Business meeting at USCAP 2026 Annual meeting in San Antonio. The scientific theme is genitourinary pathology and detailed in the attached CAPA annual business meeting agenda.

5) CAPA-DPA collaboration

CAPA maintains its status as an allied society of the Digital Pathology Association (DPA). Through this partnership, CAPA receives continued financial support and members benefit from complimentary DPA memberships, strengthening our shared efforts to expand digital pathology education and outreach.

3. Enhancing Member Engagement, Well-Being and Leadership Development

Led by Drs. Helen Zhang, Haijun (Steven) Zhou, and Qiuying Shi, the program offers a diverse series of lectures and events spanning leadership and communication, professionalism, academic advancement, and health and wellness. Together, these activities foster both professional growth and personal well-being, helping to sustain a strong and resilient CAPA community.

4. Strengthening CAPA's Financial Foundation

To ensure the long-term sustainability and continued growth of CAPA, we are actively pursuing financial sponsorships from industry partners. Under the leadership of Dr. Yi Ding, Chair of the Professional Partnerships Committee, we are recruiting sponsors to support the CAPA Annual Business Meeting at the USCAP 2026 Annual Meeting.

Finally, I extend my sincere gratitude to all our members for your dedication and support. Your collective efforts are the driving force behind CAPA's continued vitality, impact in the field of pathology, and sustained growth.

Sincerely,

Zaibo Li, MD PhD MBA
CAPA President (2025–2026)



CAPA Election Committee

Dear CAPA Members,

The CAPA Election Committee is pleased to announce the opening of nominations for the 2026-2028 Board of Directors (BOD), the 2026-2027 CAPA **President**, the 2026-2027 CAPA **President-elect** positions according to the CAPA bylaws and the amendment 1 (enclosed). **Four (4) BOD** positions are available, along with the positions of CAPA **President** and **President-elect**.

Nomination Process:

We welcome all qualified candidates, whether self-nominated or nominated by others. To apply, candidates must submit:

- A brief biography (maximum 450 words)
- A recent portrait
- CAPA Qualification Validation Election Questionnaire (enclosed)

Please send submissions to the Election Committee at gao.john@mhsil.com by 12:00 PM EST, December 31, 2025. The final list of qualified candidates will be published on the CAPA website by January 16, 2026.

Election Timeline:

- **BOD Election:** Voting by CAPA members will take place from **12:00 PM EST, January 30, 2026 (Friday), to 12:00 PM EST, February 1, 2026 (Sunday)**. Election results will be announced about one week.
- **President & President-elect Election:** The CAPA President and President-elect will be elected by the current BOD, with results announced as soon as they are finalized.

We appreciate your active participation in the 2026 CAPA election. Your involvement is vital to the success of our organization's democratic process.

Thank you,
CAPA Election Committee

The Current Bylaws of CAPA Article VII:

SECTION 1. Election of BOD members by CAPA members

1. The candidate for a BOD member shall be a lifetime member or regular member for at least three consecutive years and who has been actively involved in CAPA activities. The candidates of the BOD shall register with Election Committee and the eligibility shall be reviewed by the Election Committee.
2. The BOD members shall be elected by majority votes of CAPA members.
3. The election results shall be announced by the Election Committee.
4. Members of the BOD may run for a second term or run for President, both with a minimum of one intervening year of not serving as a member of the BOD before the new term.



SECTION 2. Election of President by the BOD

1. The candidate for President shall be a lifetime member or regular member for at least five consecutive years, who has been actively involved in CAPA activities, and who has served at least one full term of the BOD or EC member, Treasurer, or as chair of CAPA committee (co-chairs and subcommittee chairs excluded). Eligibility shall be reviewed by the Election Committee.
2. The candidate with a simple majority of votes shall be elected as the President by the BOD. If multiple candidates are present and no one attains a simple majority in the first round of voting, additional round(s) of voting on the top two candidates by the prior voting results shall be required until one candidate attains a simple majority of votes. If there are multi-way tie, a ranked voting can be used to break the tie so as to select out the top two candidates for additional round(s) of voting.
3. There shall be no anonymous vote and the voting records are open to the general members.
4. The results shall be announced by the BOD.
5. The President can run for the same position or a BOD position with a minimum of five intervening years between the terms.

Amendment 1 to Article VII of CAPA Bylaws: "President-Elect of CAPA"

Election Timeline:

The election of the President-Elect by the Board of Directors (BOD) shall occur concurrently with the election of BOD and/or the President when occurred by eligible members, as applicable.

President-Elect Responsibilities:

The President-Elect shall serve as a regular member of the Executive Committee (EC) and perform all duties associated with that role. The President-Elect will work closely with the President, providing support and assistance in fulfilling the President's responsibilities, under the leadership of the President of CAPA.

Initial Election:

After the amended Bylaws taken effect, the elections for both President and President- Elect positions shall occur simultaneously, and these roles shall be filled accordingly.

Subsequent Elections:

In subsequent years, elections will be conducted solely to fill the President-Elect position.

Call for Applications: 2026 CAPA Young Investigator Award and Distinguished Pathologist Award

On behalf of the Board of Directors of the Chinese American Pathologists Association (CAPA), we are pleased to announce the opening of applications for the 2026 CAPA Young Investigator Award and Distinguished Pathologist Award.

Young Investigator Award

The Young Investigator Award, generously supported by an anonymous donor, will be awarded annually to a pathologist who meets the following criteria. One award will be presented each year. If no suitable candidate is identified, the \$500 prize will roll over to the next year, allowing for up to two awards in that year.



Eligibility criteria:

1. Active or lifetime CAPA membership for a minimum three consecutive years, with significant contributions to the CAPA community.
2. Within 10 years post-residency or fellowship training at the time of nomination (e.g., for the 2026 award, candidates must complete their last training in residency or fellowship in June 2016 or later).
3. One of the following three scientific contribution metrics:
 - a) Holding or having held an extramural research grant (e.g., R01, R21, R03, NSF small, NSF CAREER, NSF EAGER) as PI, or a trainee grant such as T32 and/or K08 as a mentor.
 - b) At least twenty Pubmed-indexed, peer-reviewed original research publications as first or senior author within 10 years (excluding case reports, images, and commentaries).
 - c) Five first or senior-authored original research publications within 10 years, each with >50 citations, OR five such publications in journals each with an impact factor >5 (a combination of these two criteria is acceptable, e.g., two publications each with citations >50 and three publications in journals each with an impact factor >5).

The Distinguished Pathologist Award will be presented annually to a pathologist who meets the following criteria.

Eligibility criteria:

- a. Active or lifetime CAPA membership for at least three consecutive years and a minimum 10 years of post-residency and fellowship experience.
- b. Significant service contributions to the pathology community, including CAPA and/or other pathology societies. This can include leadership roles at departmental, institutional, or society level, participation in society committees, service on journal editorial boards, or contributions as a lecture for society events.
- c. Significant scientific contribution to a pathology subspecialty, demonstrated by substantial grant support (e.g., NIH R01) OR meeting one of following publication criteria post training:
 - i. 40 Pubmed-indexed, peer-reviewed publications as first or senior author in highly-regarded journals.
 - ii. 30 such publications as first or senior author, with at least 10 published in journals with an impact factor >5.
 - iii. 20 such publications as first or senior author, with at least five published in journals with an impact factor >10 (a combination of ii and iii is acceptable).

(Note: Peer-reviewed publications include any type of original research in experimental, translational, or clinical research, as well as reviews, but excluding single-case reports, images, author responses, and commentaries. A book chapter as first or senior author is counted as one publication. Editorship in WHO or AFIP series meets the scientific criteria for this award. Editorship in other books is counted as five publications per book. Any achievement in service, teaching, research, and administration will be valued.)

Submission and Deadline: Both self-nominations and peer nominations are welcome. To apply, please submit your CV along with a summary of qualifications to Dr. Limin Yu at limin.yu@hipatho.com by January 15, 2026.

Notification of Awardees: Awardees will be notified by the end of February 2026

For any questions or additional information, please contact Dr. Limin Yu at limin.yu@hipatho.com



Call for Submissions for 2026

CAPA-GoPath Best Abstract Award

On behalf of the Chinese American Pathologists Association (CAPA) Award Committee, we are excited to invite submissions for the CAPA-GoPath Best Abstract Award. This award is made possible by the generous support of GoPath Diagnostics (<https://gopathdx.com/>), a leading full-service laboratory specializing in cancer genetics, molecular, and anatomic pathology based in Buffalo Grove, Illinois.

Eligibility Criteria:

1. Applicants must be trainees of Chinese ethnicity (residents or fellows) currently enrolled in an accredited pathology training program in North America.
2. Eligible trainees must be CAPA associate members at the time of application and must maintain their membership status through when the award is conferred.
3. Applicants must be the first author of an abstract accepted for presentation at the USCAP 2026 Annual Meeting.

Application Requirements:

To apply, please submit the following documents or information:

1. Abstract(s) accepted for presentation at the USCAP 2026, in Word format, including the complete list of authors and their institutional affiliations.
2. USCAP abstract acceptance letter(s). If your work was selected for platform presentation, please include that notification as well.
3. Your full name and the name of your residency/fellowship program to verify your current training status.

Timeline:


All applications must be submitted by January 5, 2026. Awardees will be invited to deliver a brief oral presentation in late February or early March 2026 to determine the 1st-, 2nd-, and 3rd-place rankings. Final results will be announced in March 2026. The awards-consisting of a certificate and a monetary prize-will be presented at the 2026 CAPA Annual Meeting (CAPA Companion Society Meeting) during the USCAP Annual Meeting in March 2026 in San Antonio, TX.

Contact Information:

For any questions or to submit your application, please contact Dr. Shimin Hu at shu1@mdanderson.org or Dr. Huina Zhang at Huina_Zhang@URMC.Rochester.edu.

Call for Self-Nomination for 2026 CAPA-Lizhen Gui Award

The Lizhen Gui Award was established by the Chinese American Pathologists' Association (CAPA) in 2020, thanks to the generous donation from Dr. Lizhen Gui, a lifetime CAPA member and a passionate advocate for the Chinese American pathology community. Dr. Gui is known for her commitment to exceptional clinical training, lifelong learning, and philanthropy. This award honors one or two outstanding pathologists-in-training each year, contingent upon fund availability.



1. Applicants must be residents or fellows currently enrolled in an accredited pathology training program in North America.
2. Applicants must be CAPA associate members at the time of application, have not previously received the Lizhen Gui Award, and maintain their membership status through the year the award is conferred.
3. Self-nominations will be accepted. Previous applicants who did not receive the award are encouraged to reapply.

Applicants should submit the following documents:

- ### Timeline:

All application materials, including the CV, summary, and a reference letter from the applicant's training program director, must be submitted by January 5, 2026. Applicants will be notified of the decision in February 2026. The award will be presented at the 2026 CAPA Annual Meeting (CAPA Companion Society meeting) during the USCAP Annual Meeting in March 2026 in San Antonio, TX.

Contact Information:

For any questions or to submit your application, please contact Dr. Huina Zhang at Huina_Zhang@URMC.Rochester.edu or Dr. Shimin Hu at shu1@mdanderson.org.

CAPA Members Achievements

Congratulations to Dr. Liang Cheng!

The 2026 special edition marks Professor Liang Cheng's third time as Editor of Histopathology ARI, following his editor's role in the 2012 and 2019 ARIs. He is the current President of The International Society of Urological Pathology (ISUP) and holds a world record i10-index of 1024, with an h-index of 138.





Professor Liang Cheng, Vice Chair, Director of Anatomic Pathology, and Director of Molecular Pathology at Brown University Warren Alpert Medical School, Brown University Health, is co-editor of the 2026 Annual Review Issue (ARI)

of *Histopathology*. Launched 20 years ago in 2006 by Dr. Christopher Fletcher, the *Histopathology* ARI is one of the most influential annual review publications in diagnostic surgical pathology. In addition to his editorial role, Dr. Cheng contributed nine articles to the 2026 *Histopathology* ARI. The full content of this special edition is available at the following link:

<https://onlinelibrary.wiley.com/toc/13652559/2026/88/1>

[Annual Review Issue: Genitourinary Pathology: Histopathology: Vol 88, No 1](#)

Congratulations to Dr. Lirong Cheng!

Winner of the Cecil Cutting Leadership Award in June 2025.

Winner of the 8th “Fok Ying Tung Award for Outstanding Chinese Heritage Physicians Worldwide” of the World Association of Chinese Doctors (WACD).

Congratulations to Dr. Huihua Li!

Appointment/Promotion: Autopsy Director (effective 1/1/2026), Department of Pathology, Duke University Medical Center.

Community service: CAP immunohistochemistry (IHC) committee, member, 2025-2029.

Congratulations to the following CAPA members for their achievements!

Peer Reviewed Publications (First author or last author only, alphabetic order):

Gang He. From Rejection to Residency: Reflecting on two decades of mentoring with perseverance, redemption and the quiet power of helping others find their light. *The Pathology*, 11/21/2025.

Gang He. Pressure Makes the Pathologist: Revisiting the high demands of the Hot Seat rotation in pathology fellowship training. *The Pathologist*, 06/16/2025.

Li Jiannan, Tanager Kevin, Setia Namrata. Collagenous gastritis: clinical features, histologic correlates and unanswered questions. *Histopathology*. 2025 Dec;87(6):789-801. doi: 10.1111/his.15542. Epub 2025 Sep 5. PMID: 40911031; PMCID: PMC12605687.

Mengxue Zhang, Yan Zhou, Chrystalle Katte Carreon, Ann Nguyen, Tiana Riley, Aliya N Husain, **Huihua Li**. Clinical Significance of C4d Positivity Within the First Month after Heart Transplantation in Detecting Antibody-Mediated Rejection on Endomyocardial Biopsies. *Cardiovasc Pathol*. 2025 Sep 20;80:107783. doi: 10.1016/j.carpath.2025.107783

Book Chapters (First author or last author only, alphabetic order):

Huihua Li and Victor L. Roggli. “Asbestos Bodies and Non-asbestos Ferruginous Bodies.” In *Pathology of Asbestos-Associated Diseases*, edited by Tim D. Oury et al., Springer Nature, 2025, Chap 3, pp. 59–84. https://doi.org/10.1007/978-3-031-89250-9_3

Huihua Li, Carolyn H. Glass, and Victor L. Roggli. “Carcinoma of the Lung.” In *Pathology of Asbestos-Associated Diseases*, edited by Tim D. Oury et al., Springer Nature, 2025, Chap 7, pp. 225–246. https://doi.org/10.1007/978-3-031-89250-9_7



Book Chapters (First author or last author only, alphabetic order):

Huihua Li, Anupama Sharma, and Victor L. Roggli. "Analysis of Tissue Mineral Fiber Content." In Pathology of Asbestos-Associated Diseases, edited by Tim D. Oury et al., Springer Nature, 2025, Chap 11, pp. 335–378.

Mengxue Zhang, Hongzhang Mei, Qiong Zhang. Pharmacogenomics-Guided Chemotherapy in Colorectal Cancer: From Bench to Bedside. Last Research on Colorectal Cancer. IntechOpen. DOI: 10.5772/intechopen.1012381. 2025

Qiong Zhang, **Min Cui**. Section 9: Rare tumors of the pancreas (PeComa) of 100 Rare Tumors of the Digestive System: A Case-Based Reference for Surgical Pathologists. Edition 1, Elsevier, Hardback ISBN: 9780443220616; eBook ISBN: 9780443220623. 2025.

Agenda of 2026 CAPA Annual Business Meeting and Dinner

Time:	March 21, 2026, 12:00 tp 4:00 pm
Location:	Marriott Rivercenter (Room TBD)
12:00-12:30 pm	Registration and Lunch (provided)
12:15-12:45pm	Presentations by Industry Sponsors
12:45-2:30pm	Scientific section: CAPA-German Society of Pathology (DGP) Companion Meeting, chaired by Dr. Xiaoying Liu

	Title	Speakers	Institution
12:45-1:05 pm	Intraductal Proliferations of the Prostate Results of the GUPS/ISUP Consultation	Prof. Glen Krisiansen	Bonn University Hospital, Germany
1:05-1:25 pm	Surgical Pathology: A Powerful Tool to Discover Novel Therapeutic Targets of Prostate Cancer	Dr. Jiaoti Huang	Duke University School of Medicine
1:25-1:45 pm	Special Testicular Pathology-Experiences of a German Reference Center	Prof. Felix Bremmer	Goettingen University Hospital, Germany
1:45-2:05 pm	Upper Tract Urothelial Carcinoma: a True Twin of Bladder Urothelial Carcinoma?	Dr. Guoli Chen	Pennsylvania State University College of Medicine
2:05-2:15 pm	Q&A		
2:15-2:25pm	Coffee break		

• 2:25 - 2:50 pm CAPA Annual Business Reports

- Overall Report: Dr. Zaibo Li (5 min)
- BOD: Dr. Guoli Chen (3 min)
- Education Committee (including OLE Committee): Dr. Xiaoying Liu/Dr. Rong Xia (5 min)
- Membership Committee: Dr. Belinda Sun (2 min)
- Leadership, Professionalism, Wellness: Dr. Helen Zhang (3 min)
- Finance Committee: Dr. Yanjun Hou (2 min)
- International Collaboration Committee: Dr. Huamin Wang (2 min)
- JCTP report and award: Dr. Guoping Cai (3 min)



- 2:50 - 3:05 pm CAPA Award Presentation
 - CAPA Young Investigator Award presented by Dr. Guoli Chen
 - CAPA Distinguished Pathologist Award presented by Dr. Guoli Chen
 - CAPA Honorary Award, presented by Dr. Zaibo Li
 - CAPA President Award, presented by Dr. Zaibo Li
 - CAPA Outstanding Service Award, presented by Dr. Zaibo Li
 - CAPA Service Award, presented by Dr. Zaibo Li
 - CAPA-HiPatho Special Contribution Award (JCTP), presented by Dr. Zaibo Li
 - CAPA-NovinoAI Education Service Award, presented by Dr. Rong Xia
- 3:05-3:15 pm 2025 CAPA-GoPath Best Abstract Award Session, presented by Dr. Shimin Hu with GoPath CEO, Dr. Jim Lu
2025 Lizhen Gui Award, presented by Dr. Shimin Hu and Dr. Lizhen Gui
- 3:15-3:35 pm Speeches by other pathology society leaders (USCAP, CAP, CSP, ASCP, DGP, ASC, DPA, AMP)
- 3:35-3:45 pm Special thanks to retiring BOD members and EC members (Dr. Zaibo Li) and to introduce new BOD members (Dr. Limin Yu)
- 3:45-3:50 pm Message from CAPA President of 2026-2027
- 3:50-4:00 pm Group pictures at the conference room

Please join us at the CAPA Annual Business Dinner



Time: Sunday, March 22, 2026, 6:00 – 9:00 pm

Banquette Location: Casa Rio

430 E Commerce St, San Antonio, TX 78205

Zaibo Li, MD, PhD, MBA (CAPA President 2025-2026)
& Executive Committee



Message from the Chair, CAPA Online Education Committee

As we welcome the New Year, I would like to thank our speakers, moderators, and participants for making the CAPA Online Education Program a continued success. This past year, we hosted 31 online CME sessions, 2 special educational sessions, and supported 10 leadership and wellness programs, along with 2 industry-sponsored sessions.

In the coming year, we look forward to exploring key topics including cytopathology, women's health pathology, and hematopathology, as we continue to provide high-quality, relevant educational content for our community.

Thank you for your continued engagement and support. Wishing everyone a healthy and successful New Year.

Warm regards,
Rong Xia, MD, PhD
Chair, CAPA Online Education Committee

Upcoming CAPA OLE Schedule

1/04/2026	No Lecture (New Year)
1/11/2026	Transforming Pathology Practice: AI-Driven Whole Slide Imaging Interpretation Quincy Gu
1/18/2026	EUS-FNA of solid pancreatic lesions: caveats and pitfalls Brant Wang
1/25/2026	TBD
2/01/2026	Cervical cancer screening updates and diagnostic challenges Tianle Zou
2/08/2026	Pancreas Cytopathology 7:00-7:40PM Qun Wang Biomarkers for pancreatic ductal adenocarcinoma 7:40-8:20PM Hannah Chen
2/15/2026	No Lecture (Chinese New Year)
2/22/2026	TBD
3/01/2026	Kidney Cytopathology Xiaoqi Lin
3/08/2026	Practical Diagnostic Challenges in Pulmonary Cytology and Proposed Resolutions Jian Jing/Zhengwei Dong
3/15/2026	The Milan system for reporting salivary gland cytology Tieying Hou
3/22/2026	TBD
3/29/2026	No Lecture (USCAP)



CAPA Acknowledges the Following Sponsors for Their Support

Platinum Sponsor:




Gold Sponsor:



2026 CAPA BOD, President and President-elect Election

January 07, 2026

Dear CAPA Members:



The CAPA Election Committee is pleased to announce that six (6) nominated and qualified candidates, as per CAPA bylaws, will be running to fill four (4) positions on the Board of Directors (BOD) for the 2026-2028 term. Additionally, two (2) nominated and qualified candidates will be running for the President and President-elect positions for the 2026-2027 term.

The qualified BOD candidates are listed alphabetically below, along with their enclosed [biographies](#). Voting for the BOD positions will be open to **all eligible CAPA members** and will take place from **Friday, January 30, 2026, at 12:00 pm (noon) EST** to **Sunday, February 1, 2026, at 12:00 pm (noon) EST**.

The qualified President and president-elect candidates are also listed alphabetically below, along with their enclosed [biographies](#). Voting for the President position will be conducted by CAPA **BOD only** and will occur during the same timeframe: **Friday, January 30, 2026, at 12:00 pm (noon) EST** to **Sunday, February 1, 2026, at 12:00 pm (noon) EST**.

Thank you for your participation in this important election!

John Gao, MD, PhD

CAPA Election Committee

Candidates for President and President-elect

Dr. Xiaoying Liu (President-elect)

Dr. Zenggang Pan (President)

Candidates for BOD

Dr. Di (Andy) Ai

Dr. Liam Chen

Dr. Huihua Li

Dr. Qun Wang

Dr. Yu Yang

Dr. Huina Zhang

Zenggang Pan, M.D., Ph.D.

Professor of Pathology
Director of Hematopathology
Chair of Pathology Finance Committee
Department of Pathology
University of Colorado School of Medicine




Dr. Zenggang Pan earned his medical degree from Peking University Health Science Center (Beijing Medical University) and then completed his Ph.D. at University of Nebraska Medical Center. Following this, he pursued his anatomic and clinical pathology residency training at Creighton University Medical Center, surgical pathology fellowship training at University of Alabama at Birmingham, and hematopathology fellowship training at City of Hope National Medical Center.

Currently, Dr. Pan serves as a Professor of Pathology, Director of Hematopathology, and Chair of Pathology Finance Committee at University of Colorado School of Medicine. His professional focus includes hematopathology, head/neck pathology, and frozen service. Dr. Pan has a strong interest in medical education and has devoted a large amount of time and efforts in teaching and mentoring pathology trainees and junior attending. He had served as the associate program director of pathology residency training in both Yale University and University of Colorado. Over his career, Dr. Pan has published more than 70 scientific articles and contributed multiple book chapters. He has served as a section or associate editor and as a member of editorial boards for several pathology-related scientific journals. Additionally, Dr. Pan has been actively involving in pathology billing and coding practices, and served in the RUC/CPT subcommittee under Economic Affairs Committee (EAC) of College of American Pathologists (CAP).

The Chinese American Pathologists Association (CAPA) played significant roles in Dr. Pan's career development. He has been a dedicated member of CAPA, a commitment that began during his residency. He had served on the CAPA Board of Directors and the Executive Committee, and he had served as Chair of the Education Committee, Chair and Co-founder of Online Education Committee, and Chair of Membership/Website Committee. Dr. Pan had been actively involving in organizing CAPA Annual Diagnostic Courses and Business Meetings. His contributions have been recognized with several honors, including the CAPA President Outstanding Service Award and the Member of the Year Award.

Dr. Pan views CAPA as a unique and vital organization, and he remains deeply committed to its mission. He aims to address CAPA members' professional needs, foster career development, and enhance collaboration within the CAPA community and among other organizations and societies. He also intends to advance educational activities for trainees and practicing pathologists. Through these efforts by working closely with CAPA members, Dr. Pan seeks to propel CAPA to another level nationally and internationally by serving as the CAPA President, which offers an exciting prospect to synergize with esteemed colleagues, exchange ideas, spur innovation, and effect positive transformations in the field of pathology.

Dr. Xiaoying Liu, MD, is an Associate Professor and Director of Cytopathology at Dartmouth-Hitchcock Medical Center and a dedicated lifetime member of the CAPA. Throughout her career, she has remained deeply committed to CAPA, contributing across education, scientific programming, governance, industry relations, and international collaboration. CAPA has been central to her professional development, and she has consistently worked to advance its mission, visibility, and impact within the pathology community.



As Chair of the Cytopathology Subcommittee (2022–2024), Dr. Liu led the development of a comprehensive 10-lecture online cytopathology education series and delivered multiple invited lectures. She also served as Chief Guest Editor for a special cytopathology issue of *Human Pathology Reports*, overseeing 12 invited review articles. This work earned the journal's 2024 Outstanding Editorial Contribution Award, reflecting her commitment to high-quality scholarly education.

Dr. Liu's long-standing service to CAPA education includes roles as Co-Chair of the Education Committee (2023–2025) and Chair (2025–2026). In these capacities, she helped organize the 9th and 10th CAPA Diagnostic Courses and later served as Chair of the Scientific Committee and organizer for the 11th CAPA Diagnostic Course in 2025, overseeing scientific planning, speaker recruitment, and program development. She also co-chaired the CAPA Online Education Committee (2024–2025) and the Pathology Informatics and Digital Pathology Subcommittee (2023–2025), delivering lectures focused on AI-enabled cytology.

Dr. Liu chaired the CAPA–ASC Companion Meeting Committee, organizing several high-impact sessions, including the 2024 program on digital cytopathology and artificial intelligence, which achieved strong attendance and visibility. She also chaired CAPA–DGP (German Society of Pathology) companion meetings in 2025, collaborating with German experts to strengthen CAPA's international partnerships.

Dr. Liu chaired the scientific sessions for CAPA's 2024 and 2025 Annual Business Meetings and will chair the 2026 session. In these roles, she developed meeting schedules, invited speakers, and supported program planning for CAPA's flagship annual events. She has also strengthened CAPA's financial foundation. As Chair of the Industry Relations Committee (2024–2025), she engaged industry partners, secured sponsorships, and helped raise substantial support for the 2025 Annual Business Meeting.

Her governance service includes roles as Assistant Secretary of BOD, Secretary of BOD, and member of the CAPA Executive Committee. She has organized board meetings, supported bylaw revisions, promoted award elections, and facilitated collaborations with the CAP, ASC, and the German Society of Pathology. Her contributions have been recognized with the 2024 CAPA Distinguished Service Award and the 2025 CAPA President's Award.

If elected President-Elect, Dr. Liu is committed to expanding CAPA's educational reach, enhancing member engagement, supporting early-career development, and advancing innovation and international collaboration across pathology. She views CAPA as a vital professional home and is dedicated to guiding its continued growth and success.

Dr. Di (Andy) Ai, MD, PhD, FCAP, is an academic surgical pathologist currently serving as Assistant Professor of the Department of Anatomic Pathology at The University of Texas MD Anderson Cancer Center. He is a board-certified pathologist with subspecialty expertise in breast pathology, supported by fellowship training in both breast pathology and oncologic surgical pathology at MD Anderson. Dr. Ai's academic career spans leading institutions including Emory University, UTHealth Houston and MD Anderson, reflecting a strong commitment to excellence in clinical service, research, education, and professional leadership.



Dr. Ai has maintained an active and sustained involvement with the Chinese American Pathologists Association (CAPA) since 2016 and is a lifetime member since 2021. His leadership within CAPA includes service as Director of the Immunohistochemistry Subcommittee, Director/ Associate director of the IT and Website Subcommittee, as well as Associate Director of the Membership Subcommittee. In recognition of his dedicated contributions, Dr. Ai received the CAPA Service Award in 2024. These roles have provided him with firsthand experience in organizational governance, strategic planning, digital infrastructure, and member engagement—skills directly relevant to service on the CAPA Board of Directors.

Academically, Dr. Ai has a strong national and international profile. He has authored several book chapters and 35 publications in high-impact journals, such as *Modern Pathology*, *Histopathology*, *Breast Cancer Research and Treatment* and *Proceedings of the National Academy of sciences of the United States of America*, with particular focus on biomarkers, breast pathology and basic/translational research. He also published nearly 40 abstracts presented at regional, national and international conferences, including 5 oral presentations, reflecting sustained scholarly productivity and active engagement with the pathology community. He currently serves as Co-Investigator on a NIH-funded R01 grant, demonstrating success in funded research. His work bridges translational research, diagnostic practice, and clinical outcomes.

Dr. Ai is also deeply committed to education and mentorship. He is an active lecturer for pathology residents, regularly supervises undergraduates, medical graduates and research trainees. His teaching philosophy emphasizes rigor, clarity, and commitment to mentorship, which expands to foreign medical graduates seeking pathology training in the United States. His mentees have been admitted into medical school and residency program in the past few years. He also participates in medical school admissions and academic service committees.

With a career that integrates clinical excellence, scholarly productivity, organizational leadership, and service to the Chinese pathology community, Dr. Ai will bring both vision and practical experience to the CAPA Board of Directors. He is dedicated to advancing CAPA's mission of professional development, academic collaboration, and advocacy for Chinese pathologists nationwide.

Dr. Liam Chen is a Professor in the University of Minnesota Medical School and serves as Director of the Neuropathology Division and Director of the Neuropathology Fellowship Program. He also provides clinical leadership as Director of the Minnesota David Tomassoni Biorepository Center and Director of the Immunohistochemical Laboratory at M Health Fairview.



Dr. Chen earned his medical degree (Bachelor of Medicine) at Shandong University, followed by a PhD at the University of Alberta. He completed postdoctoral training at Harvard Medical School, anatomic pathology residency at Brigham and Women's Hospital, and fellowships in molecular genetic pathology and neuropathology at Harvard Medical School. He is board certified in anatomical pathology, neuropathology, and molecular genetic pathology. Dr. Chen's scholarly work spans translational neuropathology, molecular diagnostics, neurodegeneration, and CNS tumor pathology. His research has been supported by both federal and foundation funding. Dr. Chen has over 100 scholarly works including research articles, reviews, and book chapters, and have received over more than 15,000 citations. He is the chief editor for journals including *Diagnostics* and *Journal of Neurology Research*. In addition, Dr. Chen serves as a member in multiple editorial boards, grant evaluation and review bodies including NIA/NIH and Department of Defense.

Dr. Chen is a life member of CAPA and has served as the Chair of Neuropathology Subcommittee since 2020.

Dr. Huihua Li is an Assistant Professor at the Department of Pathology, Duke University Medical Center. He practices Thoracic/Pulmonary, Cardiovascular, and Autopsy Pathology. Dr. Li completed his residency in a combined Anatomic and Clinical Pathology at the University of Wisconsin-Madison (2018-2022), followed by a dedicated Thoracic and Surgical Pathology Fellowship at the University of Chicago (2022-2023). Before his residency, Dr. Li pursued PhD and postdoctoral training at the University of Pittsburgh Medical Center where his research focused on acute lung injury, idiopathic pulmonary fibrosis, and lung immunology; these efforts had resulted in two NIH R01 grants.



Dr. Li currently serves as an Associate Director of Duke Autopsy service and will step into the Director role on January 1, 2026. He also serves as a member of Duke University Biosafety Committee (IBC) and Biosafety Review Committee (IBRC). As a dedicated educator, Dr. Li has taught Pathology courses to Duke medical students since he joined Duke in 2023. He has been actively involved in Duke Pathology Residency interviews annually, and he enjoys working with residents and serving as a mentor.

Dr. Li is a member of the College of American Pathologists (CAP) Immunohistochemistry Committee, he also plays active roles in national pathology societies including Pulmonary Pathology Society, Society for Cardiovascular Pathology, and the International Mesothelioma Panel. Dr. Li is enthusiastic about research. As a primary investigator, he received a research grant from the Lung Cancer Initiative for his project focusing on “CXCR2 Expression in Lung Neuroendocrine Neoplasms” (07/2024-12/2025). Dr. Li has published 4 book chapters as a first author and over 30 peer-reviewed publications and numerous conference abstracts. He was invited to review manuscripts for prestigious journals such as *Archives of Pathology & Laboratory Medicine*, *International Journal of Surgical Pathology*, *Journal of Clinical and Translational Pathology*, and *Scientific Reports*, etc.

Dr. Li has been actively engaged in CAPA activities. He serves as a member of CAPA Award Committee and Thoracic Subcommittee. Dr. Li presented a lecture entitled “Morphologic Spectrum of Cardiac Diseases: Insights from Explanted and Post-Mortem Hearts” at the 11th CAPA Diagnostic Course (09/2025) at Orlando, FL as well as a lecture entitled “Mesothelioma and Mesothelial Tumors” at the 9th CAPA Diagnostic Course (09/2023) at Denver, CO. His other CAPA activities included lecturing in CAPA’s online education program and in Zhejiang/CAPA Thoracic Pathology Symposium.

Dr. Li is thrilled to contribute more and make the best effort to serve all CAPA members. He looks forward to the opportunity to work with other leadership members to polish CAPA pathologists’ diagnostic skills by strengthening the educational activities, to enhance CAPA’s influence by collaborating more and deeply with other organizations, and to prompt every member’s success within and beyond CAPA.

Dr. Qun Wang is an Associate professor in the Department of Pathology at Emory University School of Medicine. She is deeply committed to education, service, and research, and has been actively engaged in professional leadership at the local, national, and international levels.



At Emory, Dr. Wang serves on several institutional committees, including the Pathology Education Committee, Pathology QA Committee, Digital Pathology Committee, and the Emory Winship Network Cancer Committee. She has mentored numerous trainees on research projects that have resulted in national and international presentations and peer-reviewed publications. Dr. Wang has authored more than 100 professional works, including peer-reviewed articles, abstracts, and case studies, and has presented extensively at national and international conferences. Her contribution to medical education, clinical service, and research has been recognized through multiple honors, including Emory School of Medicine Educator Appreciation Day (2023- 2025), National Doctors' Day, (2025), the Research Award for the Global Ring Study for HER2 IHC Testing in Breast Cancer (2023), Researcher Appreciation Day (2025), and the 2024 Departmental Outstanding Service Award.

Nationally and internationally, Dr. Wang contributes to the American Society of Cytopathology (ASC) as a member of the Membership Committee and the Case Study Committee, where she authors and reviews educational content. She also serves on the Papanicolaou Society of Cytopathology (PSC) Research Award Committee, reviewing and scoring trainee-authored abstracts submitted to the USCAP Annual Meeting, assisting in the selection of the "First-place" and "Second place" awards. In addition, she is a mentor in the ASC Dyadic Mentorship Program under the Mentoring and Pathway Committee.

Dr. Wang is also committed to global cancer education through her involvement with the Partnership of Emory and Allies for Cancer and Education (PEACE), where she serves as a lecturer, moderator, and member of the Annual Symposium Planning Committee.

Regionally, Dr. Wang holds multiple leadership roles within the Georgia Association of Pathology (GAP), including Board Member, Chair of the Membership Committee, and Co-Chair of the Education Committee. She also serves on the GAP Annual Meeting Organizing Committee and Abstract Review Board, supporting professional development for pathologists across Georgia.

Dr. Wang has been actively engaged in CAPA initiatives and strongly supports its mission. She currently serves as Chair of the CAPA Cytopathology Subcommittee and developed the 2026 CAPA Cytopathology Online Lecture Series (Cytopathology Bootcamp). She has also served on the CAPA Education Committee, the 11th CAPA Diagnostic Course and CAPA-CAP Companion Meeting Organizing and Scientific Committees (2025), and as a moderator for the 2025 CAPA-ASC Companion Meeting. Additionally, she was an invited faculty speaker for the 8th and 10th CAPA Diagnostic Courses.

Dr. Yu Yang earned her M.D. from Weifang Medical University and an M.S. from Peking University Health Science Center. She completed an Anatomic and Clinical Pathology residency at Wake Forest Baptist Medical Center, where she served as chief resident, followed by a hematopathology fellowship at Vanderbilt University Medical Center. She is a board-certified hematopathologist, a Clinical Assistant Professor, and the Medical Director of the Pathlabs Core Lab at the University of Florida.



An active member of the Chinese American Pathologists Association (CAPA) since 2020, Dr. Yang serves on the CAPA Newsletter Committee (since 2022), has been faculty at CAPA's 9th Annual Meeting (2023), and was an invited lecturer at the 11th CAPA Annual Diagnostic Course (2025). She also engages regularly in CAPA's weekly lectures, underscoring her sustained commitment to the society's educational mission.

Her leadership development includes the College of American Pathologists Engaged Leadership Academy and the University of Florida College of Medicine Leadership Academy, experiences that strengthened her skills in communication, collaboration, and strategic planning.

With a blend of clinical expertise, laboratory leadership, and dedicated service to CAPA's mission, she is prepared to be an effective member of the Board of Directors and contribute to the organization's continued success.

Dr. Huina Zhang, MD, PhD, is an Associate Professor of Pathology and Director of gynecologic pathology in the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center, with subspecialty expertise in breast and gynecologic pathology. I received MD and PhD degrees in China, followed by residency training in Combined Anatomic and Clinical Pathology at Loma Linda University Medical Center. I subsequently completed a clinical instructorship in breast and gynecologic pathology at Magee-Womens Hospital of the University of Pittsburgh Medical Center.



I have been actively and consistently engaged in professional service within national and international pathology societies. Since 2023, I have served as faculty for the College of American Pathologists (CAP) Multidisciplinary Breast Pathology Program and has been a member of the Pathologist Advisory Group for the CAP Multidisciplinary Breast Pathology Education Program since 2024. I also served on the Abstract Review Board for the Breast Pathology Section of the United States and Canadian Academy of Pathology (USCAP) between 2021 and 2024. In addition, since 2021, I have held multiple roles within the Chinese American Pathologists Association (CAPA), including serving as a member, co-chair, and chair of the Breast Pathology Committee, Immunohistochemistry Committee, and Awards Committee. I have also contributed to several institutional committees at the University of Rochester.

Beyond committee service, I serve as a section editor or editor for several peer-reviewed journals and as an ad hoc reviewer for more than 20 pathology- and breast cancer-related journals. Additionally, I am actively engaged in pathology education and have delivered more than 40 invited lectures at the institutional, national, and international levels.

My research interests focus primarily on HER2 in breast and gynecologic malignancies. I have authored nearly 100 peer-reviewed publications and contributed multiple book chapters, reflecting my sustained scholarly productivity and impact in the field.